Immunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-analysis

scientific article

Immunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-analysis is …
instance of (P31):
meta-analysisQ815382
scholarly articleQ13442814
review articleQ7318358

External links are
P356DOI10.1186/PREACCEPT-1041462276129106
10.1186/S12916-014-0150-1
P932PMC publication ID4172944
P698PubMed publication ID25199532

P50authorPaul AgiusQ78803830
Julia C CuttsQ85271181
Freya FowkesQ42800053
Julie A. SimpsonQ47172274
P2093author name stringJames G Beeson
Rosanna Powell
P2860cites workDeterminants of relapse periodicity in Plasmodium vivax malariaQ17485692
A review of malaria vaccine clinical projects based on the WHO rainbow tableQ21034112
Towards a vaccine against Plasmodium vivax malariaQ21090139
The international limits and population at risk of Plasmodium vivax transmission in 2009Q21144525
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statementQ21562278
Measuring inconsistency in meta-analysesQ27860655
Quantifying heterogeneity in a meta-analysisQ27860672
Meta-analysis in clinical trialsQ27860779
Meta-analysis of Observational Studies in Epidemiology: A Proposal for ReportingQ27861077
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infantsQ28278852
Naturally-acquired humoral immune responses against the N- and C-termini of the Plasmodium vivax MSP1 protein in endemic regions of Brazil and Papua New Guinea using a multiplex assayQ28394065
What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomesQ29615705
Plasmodium vivax merozoite surface protein-3 contains coiled-coil motifs in an alanine-rich central domainQ30738627
Humoral immune responses against Plasmodium vivax MSP1 in humans living in a malaria endemic area in Flores, IndonesiaQ30859940
Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responsesQ33333604
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.Q33350210
The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysisQ33526349
Naturally acquired antibodies to Plasmodium vivax Duffy binding protein (DBP) in Brazilian AmazonQ33617528
A Research Agenda for Malaria Eradication: Diagnoses and DiagnosticsQ33818031
A Research Agenda for Malaria Eradication: VaccinesQ33818046
Using serological measures to monitor changes in malaria transmission in VanuatuQ33998176
Serologic markers in relation to parasite exposure history help to estimate transmission dynamics of Plasmodium vivaxQ34091277
Influence of HLA-DRB1 and HLA-DQB1 alleles on IgG antibody response to the P. vivax MSP-1, MSP-3α and MSP-9 in individuals from Brazilian endemic area.Q34287358
Plasmodium vivax: clinical spectrum, risk factors and pathogenesisQ34314662
Phase I Safety and Immunogenicity Trial of Plasmodium vivax CS Derived Long Synthetic Peptides Adjuvanted with Montanide ISA 720 or Montanide ISA 51Q34546201
B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax Merozoite Surface Protein-3α (PvMSP-3α) in malaria exposed individuals from Brazilian AmazonQ34726966
A malaria merozoite surface protein (MSP1)-structure, processing and functionQ35245967
Expression and serologic activity of a soluble recombinant Plasmodium vivax Duffy binding protein.Q35551014
Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individualsQ35606249
Serologic markers for detecting malaria in areas of low endemicity, Somalia, 2008Q35877370
Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domainsQ48202726
Plasmodium vivax, P. cynomolgi, and P. knowlesi: identification of homologue proteins associated with the surface of merozoitesQ56379655
Extensive polymorphism in the plasmodium vivax merozoite surface coat protein MSP-3alpha is limited to specific domainsQ56447214
Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytesQ72590710
Immune effector mechanisms in malariaQ82383609
Sero-epidemiological evaluation of changes in Plasmodium falciparum and Plasmodium vivax transmission patterns over the rainy season in CambodiaQ35998522
New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant womenQ36330969
Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivaxQ36346627
A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies.Q36352078
The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytesQ36367429
Mapping regions containing binding residues within functional domains of Plasmodium vivax and Plasmodium knowlesi erythrocyte-binding proteins.Q36707751
Identification of Plasmodium vivax-like human malaria parasiteQ36741201
Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infectionQ36751523
ELISA detection of vivax malaria with recombinant multiple stage-specific antigens and its application to survey of residents in endemic areasQ37280061
Naturally acquired immune responses to P. vivax merozoite surface protein 3α and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean childrenQ37308698
Interpretation of tests of heterogeneity and bias in meta-analysisQ37329334
Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean childrenQ37333369
High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptomsQ37352099
The future for blood-stage vaccines against malariaQ37471465
Natural acquisition of immunity to Plasmodium vivax: epidemiological observations and potential targetsQ38079322
Development and evaluation of an immunochromatographic kit for the detection of antibody to Plasmodium vivax infection in South KoreaQ39339172
Dimorphism of the C terminus of the Plasmodium vivax merozoite surface protein 1.Q39340864
A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1.Q42581710
Merozoite surface protein-9 of Plasmodium vivax and related simian malaria parasites is orthologous to p101/ABRA of P. falciparumQ43889939
The Plasmodium vivax homologues of merozoite surface proteins 4 and 5 from Plasmodium falciparum are expressed at different locations in the merozoiteQ43919502
Plasmodium vivax Duffy binding protein: baseline antibody responses and parasite polymorphisms in a well-consolidated settlement of the Amazon RegionQ44164222
Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malariaQ44164504
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African childrenQ46182948
Comparison of immunological responses to the various types circumsporozoite proteins of Plasmodium vivax in malaria patients of KoreaQ47191626
Prevalence of antibodies to the circumsporozite protein of Plasmodium vivax in five different regions of Korea.Q47361474
Recent independent evolution of msp1 polymorphism in Plasmodium vivax and related simian malaria parasitesQ47761173
Plasmodium vivax reticulocyte binding protein-2 (PvRBP-2) shares structural features with PvRBP-1 and the Plasmodium yoelii 235 kDa rhoptry protein familyQ47855890
A reticulocyte-binding protein complex of plasmodium vivax merozoitesQ47860897
Analysis of naturally acquired antibody responses to the 19-kd C-terminal region of merozoite surface protein-1 of Plasmodium vivax from individuals in Sanliurfa, Turkey.Q47867188
Naturally acquired circumsporozoite antibodies and their role in protection in endemic falciparum and vivax malariaQ47874479
Evaluation of rapid immunocapture assays for diagnosis of Plasmodium vivax in KoreaQ47884921
Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodium vivax.Q47894112
Plasmodium vivax: Merozoites, invasion of reticulocytes and considerations for malaria vaccine developmentQ47985901
HLA class II and antibody responses to circumsporozoite protein repeats of P. vivax (VK210, VK247 and P. vivax-like) in individuals naturally exposed to malariaQ47990902
Comparison of IgG reactivities to Plasmodium vivax merozoite invasion antigens in a Brazilian Amazon population.Q48013929
Plasmodium vivax serine repeat antigen (SERA) multigene family exhibits similar expression patterns in independent infectionsQ48034847
High polymorphism in Plasmodium vivax merozoite surface protein-5 (MSP5).Q48035608
P275copyright licenseCreative Commons AttributionQ6905323
P6216copyright statuscopyrightedQ50423863
P407language of work or nameEnglishQ1860
P921main subjectPlasmodium vivaxQ311376
globulinsQ321710
blood proteinsQ425056
meta-analysisQ815382
systematic reviewQ1504425
Plasmodium vivax malariaQ18554412
protozoan antibodiesQ76122108
protozoan antigensQ76825803
P5008on focus list of Wikimedia projectScienceSourceQ55439927
P304page(s)150
P577publication date2014-09-09
P13046publication type of scholarly workreview articleQ7318358
P1433published inBMC MedicineQ4835947
P1476titleImmunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-analysis
P478volume12

Reverse relations

cites work (P2860)
Q35877857A Library of Plasmodium vivax Recombinant Merozoite Proteins Reveals New Vaccine Candidates and Protein-Protein Interactions
Q37685993A systematic review on malaria sero-epidemiology studies in the Brazilian Amazon: insights into immunological markers for exposure and protection
Q36018397An Antibody Screen of a Plasmodium vivax Antigen Library Identifies Novel Merozoite Proteins Associated with Clinical Protection
Q35970236Antibody Profiling in Naïve and Semi-immune Individuals Experimentally Challenged with Plasmodium vivax Sporozoites
Q33636850Antibody Responses to Plasmodium falciparum and Plasmodium vivax and Prospective Risk of Plasmodium spp. Infection Postpartum
Q36446343Antibody profiles to plasmodium merozoite surface protein-1 in Cambodian adults during an active surveillance cohort with nested treatment study
Q37202370Antibody responses to Plasmodium falciparum and Plasmodium vivax blood-stage and sporozoite antigens in the postpartum period
Q92016834Antibody responses within two leading Plasmodium vivax vaccine candidate antigens in three geographically diverse malaria-endemic regions of India
Q36238031B cells and antibodies in the defense against Mycobacterium tuberculosis infection
Q47204469Estimation on local transmission of malaria by serological approach under low transmission setting in Myanmar.
Q54217362Identification and immunological characterization of the ligand domain of Plasmodium vivax reticulocyte binding protein 1a.
Q41994105Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development
Q41956908IgG antibodies to synthetic GPI are biomarkers of immune-status to both Plasmodium falciparum and Plasmodium vivax malaria in young children
Q33582154Immunity as a predictor of anti-malarial treatment failure: a systematic review
Q38689264Immunity to malaria in an era of declining malaria transmission
Q90243753Imported Malaria in Countries where Malaria Is Not Endemic: a Comparison of Semi-immune and Nonimmune Travelers
Q63045331Inhibition of parasite invasion by monoclonal antibody against epidermal growth factor-like domain of Plasmodium vivax merozoite surface protein 1 paralog
Q38728598Insights into the naturally acquired immune response to Plasmodium vivax malaria
Q35678578Malaria and immunity during pregnancy and postpartum: a tale of two species
Q35712522Malaria eradication and elimination: views on how to translate a vision into reality
Q37290599Management of relapsing Plasmodium vivax malaria
Q36565070Maternal-foetal transfer of Plasmodium falciparum and Plasmodium vivax antibodies in a low transmission setting
Q26772878Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria
Q64124854Molecular detection of P. vivax and P. ovale foci of infection in asymptomatic and symptomatic children in Northern Namibia
Q46926980Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein and Clinical Immunity to Malaria in Rural Amazonians.
Q28554358Plasmodium vivax Reticulocyte Binding Proteins Are Key Targets of Naturally Acquired Immunity in Young Papua New Guinean Children
Q93012608Plasmodium vivax Reticulocyte Binding Proteins for invasion into reticulocytes
Q36155071Plasmodium vivax VIR Proteins Are Targets of Naturally-Acquired Antibody and T Cell Immune Responses to Malaria in Pregnant Women
Q48021651Probabilistic data integration identifies reliable gametocyte-specific proteins and transcripts in malaria parasites
Q36167716Protective Efficacy of Plasmodium vivax Radiation-Attenuated Sporozoites in Colombian Volunteers: A Randomized Controlled Trial
Q26826940Protein flexibility in the light of structural alphabets
Q30248811Recent insights into humoral immunity targeting Plasmodium falciparum and Plasmodium vivax malaria
Q110697512Serology for Plasmodium vivax surveillance: A novel approach to accelerate towards elimination
Q58567578Specificity of the IgG antibody response to Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, and Plasmodium ovale MSP1 subunit proteins in multiplexed serologic assays
Q55429433Structural patterns of selection and diversity for Plasmodium vivax antigens DBP and AMA1.
Q38682341T follicular helper cells regulate the activation of B lymphocytes and antibody production during Plasmodium vivax infection.

Search more.